Cancer Therapy

Enrollment completed in BLP25 liposome vaccine phase II study

Published in Vaccine Weekly, October 12th, 2005

Biomira, Inc., (BIOM, BRA) has completed the enrollment of a 20-patient phase II, single-arm, multicenter, open label study of BLP25 Liposome Vaccine (L-BLP25).

The drug is being developed in collaboration with Merck KGaA of Darmstadt, Germany.

The phase II trial will assess the safety of the formulation of L-BLP25 that the Companies plan to use in the upcoming phase III study. The phase III trial design is currently being discussed with the U.S. Food and Drug Administration.

The formulation incorporates manufacturing changes intended to secure the future commercial supply of the vaccine. Initial results from the 20-patient trial...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-10-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry